Holen Sie sich die Stockscreener-App
35.47
1.93%
0.67
Schlusskurs vom Vortag:
$34.80
Offen:
$34.88
24-Stunden-Volumen:
450.06K
Relative Volume:
0.72
Marktkapitalisierung:
$2.04B
Einnahmen:
$681.88M
Nettoeinkommen (Verlust:
$122.63M
KGV:
16.81
EPS:
2.11
Netto-Cashflow:
$220.18M
1W Leistung:
+1.52%
1M Leistung:
+4.32%
6M Leistung:
-6.26%
1J Leistung:
+6.17%
1-Tages-Spanne:
$34.64
$35.49
1-Wochen-Bereich:
$33.47
$35.49
52-Wochen-Spanne:
$26.47
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
35.47 | 2.00B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline - MSN
H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) - Insider Monkey
Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence - Investing.com Australia
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $50 at Mizuho - StreetInsider
Relief Rally in Harmony Biosciences Holdings Inc. Stock — Can It HoldEarly Entry Tips With Low Risk Zone Shared - beatles.ru
SIXS ETF Implied Analyst Target Price: $58.24 - AInvest
Harmony Biosciences Earnings Call Highlights Growth and Innovation - The Globe and Mail
Harmony Biosciences Holdings: Buy Rating Maintained Despite Q2 Earnings Miss - AInvest
Harmony targets $1B+ WAKIX sales in narcolepsy as late-stage pipeline advances - MSN
Harmony Biosciences Holdings Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Harmony Biosciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 - BioSpace
Harmony Biosciences Holdings, Inc. (HRMY): A Bullish Thesis on Strong Financials and Diversified Pipeline - AInvest
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Investing.com Canada
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Call Hi - GuruFocus
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SW - GuruFocus
Harmony Biosciences' Q2 2025: Unraveling Contradictions in ZYN002 and WAKIX Strategies - AInvest
Harmony Biosciences Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HRMY) - Seeking Alpha
Transcript : Harmony Biosciences Holdings, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: Harmony Biosciences Q2 2025 beats EPS expectations - Investing.com Canada
Harmony Biosciences Holdings: Strong Patient Growth and Promising Pipeline Support Buy Rating - TipRanks
Harmony Biosciences falls as Q2 revenue misses estimates despite profit beat - Investing.com Nigeria
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates - Yahoo Finance
Why Harmony Biosciences Holdings Inc. stock attracts strong analyst attentionSafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Harmony Biosciences Holdings, Inc. SEC 10-Q Report - TradingView
Harmony Biosciences Q2 2025 slides: revenue up 16% as WAKIX nears blockbuster status - Investing.com Canada
Topline Data from the Phase 3 registrational trial of ZYN002 in Fragile X syndrome on track for Q3 2025. - Placera.se
Harmony Biosciences : HRMY Q2 2025 Earnings Presentation FINAL - MarketScreener
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 | HRMY Stock - GuruFocus
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory - Insider Monkey
Harmony Biosciences Holdings Inc. Stages Intraday Comeback — Trend ChangeSecure Portfolio Growth Plan Review - beatles.ru
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Trading Bots Trigger Alerts on Harmony Biosciences Holdings Inc. ActivityMassive Profit Potential - beatles.ru
Published on: 2025-08-04 07:58:17 - metal.it
Is Harmony Biosciences Holdings Inc. stock overvalued or undervaluedMaximize gains with proven stock analysis - Jammu Links News
What are analysts’ price targets for Harmony Biosciences Holdings Inc. in the next 12 monthsAchieve consistent double-digit returns - Jammu Links News
Why is Harmony Biosciences Holdings Inc. stock attracting strong analyst attentionUnlock your trading potential with expert tips - Jammu Links News
What catalysts could drive Harmony Biosciences Holdings Inc. stock higher in 2025 - Jammu Links News
Harmony Biosciences Holdings Inc. Stock Analysis and ForecastTriple-digit returns - Jammu Links News
What is the dividend policy of Harmony Biosciences Holdings Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
What makes Harmony Biosciences Holdings Inc. stock price move sharplyGrow your wealth steadily and securely - Jammu Links News
When is Harmony Biosciences Holdings Inc. stock expected to show significant growthRapid capital growth - Jammu Links News
What are the latest earnings results for Harmony Biosciences Holdings Inc.Phenomenal trading returns - Jammu Links News
Should I hold or sell Harmony Biosciences Holdings Inc. stock in 2025Invest smarter with real-time trading signals - Jammu Links News
Harmony Biosciences to Release Q2 2025 Financial Results on August 5, 2025, Before Market Open - AInvest
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance
Is Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
Can Harmony Biosciences Holdings Inc. Regain Momentum After BreakdownRisk Managed Intraday Trade Alerts Increase in Volume - beatles.ru
Published on: 2025-07-31 00:25:32 - metal.it
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):